Francis Y F Lee

This inventor holds 11 USPTO granted patents and 3 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Elucida Oncology, Inc., Other. Active years: 2004-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis Y F Lee. Retrieved from https://idiyas.com/inventor/francis-y-f-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11

% Patents Active = 63.6

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 1.6

ph-index = 4

Forward Citations = 119(Granted Patents)

Company Filing History:

8 out of 3,745

Bristol-Myers Squibb Compnay

patents

2 out of 2

Elucida Oncology, Inc.

patents

1 out of 834,601

Other

patents

Years Active: 2004-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11957760 - Folate receptor targeted nanoparticle drug conjugates and uses thereof (2024-04-16),

2. 11744897 - Folate receptor targeted nanoparticle drug conjugates and uses thereof (2023-09-05),

3. 8598215 - Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases (2013-12-03),

4. 8569347 - Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases (2013-10-29),

5. 7312237 - Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases (2007-12-25),

6. 7125875 - Cyclic protein tyrosine kinase inhibitors (2006-10-24),

7. 7053069 - Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives (2006-05-30),

8. 6936628 - Oral administration of epothilones (2005-08-30),

9. 6773702 - Use of combretastatin A4 and its prodrugs as an immune enhancing therapy (2004-08-10),

10. 6727276 - Epothilone derivatives for the treatment of refractory tumors (2004-04-27),

11. 6686380 - Treatment of refractory tumors using epothilone derivatives (2004-02-03),

Title: Innovations in Cancer Treatment: The Contributions of Francis Y F Lee

Introduction

Francis Y F Lee is a notable inventor based in Yardley, PA, whose contributions to the field of oncology are underscored by his 11 patents. His pioneering work primarily focuses on the development of targeted drug delivery systems, which represent a significant advancement in cancer treatment methodologies.

Latest Patents

Among his most recent innovations are the patents related to folate receptor targeted nanoparticle drug conjugates. These nanoparticle drug conjugates (NDC) involve the use of ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates. The methods associated with these innovations offer promising new avenues for treating cancer, enhancing the precision and efficacy of therapeutic interventions.

Career Highlights

Francis Y F Lee has built a distinguished career within the pharmaceutical industry, having worked with prominent companies such as Bristol-Myers Squibb Company and Elucida Oncology, Inc. His experiences in these organizations have been instrumental in shaping his research and innovations, allowing him to contribute significantly to cancer therapeutics.

Collaborations

Throughout his career, Lee has collaborated with talented professionals, including his coworkers Kai Ma and Feng Chen. These partnerships have facilitated a rich exchange of ideas and expertise, further driving innovation in the field of drug development.

Conclusion

Francis Y F Lee's commitment to advancing cancer treatment through innovative technologies marks him as a leading figure in the pharmaceutical landscape. His work on folate receptor targeted nanoparticle drug conjugates not only illustrates his inventive spirit but also holds the potential to improve patient outcomes in oncology.

Profile summary based on public USPTO records.